Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first...

Prof Andrew Wei - Monash University, Melbourne, Australia

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first remission after intensive chemo ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL

Dr Ibrahim Aldoss - City of Hope, Duarte, USA

Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL ( Dr Ibrahim Aldoss - City of Hope, Duarte, USA )

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes...

Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston...

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups ( Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, USA )

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory...

Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA

$Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )$

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared...

Dr Martin Kaiser - The Institute of Cancer Research, London UK

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London UK )

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted...

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L...

Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora...

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL ( Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, USA )

OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Treating late relapse of paediatric ALL

Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany

Treating late relapse of paediatric ALL ( Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany )

Cancer drug policy and access in LMICs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Cancer drug policy and access in LMICs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Latest in Philadelphia chromosome-positive ALL (Ph+ ALL)

Prof Robin Foà - Sapienza University of Rome, Rome, Italy

Latest in Philadelphia chromosome-positive ALL (Ph+ ALL) ( Prof Robin Foà - Sapienza University of Rome, Rome, Italy )

OncoAlert and ecancer weekly round up for October 18th - October 23rd, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for October 18th - October 23rd, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer